File Biologics License Applications for two additional plasma collection centers
Not delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 19 Jan 2021
- Due
- 31 Dec 2021
- Checked
- 25 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“ADMA also anticipates filing BLAs for two additional plasma collection centers during 2021.”
What we found
Evidence strength A What the grades mean
The company did not report filing BLAs for two additional plasma collection centers during 2021; subsequent filings indicate only one facility had a pending BLA as of early 2022.
-
A Adma Biologics, Inc. 10-K filed 2022-03-24
“We also have one other plasma collection facility where we currently collect plasma for which a BLA is pending with the FDA.” ✓ confirmed on the page
Market reaction: the shares moved +17.8% against the S&P 500 over the three sessions around the disclosure (23 Mar 2022 to 28 Mar 2022). What this measures
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory submission
- Indicative materiality
- High rules
- Action
- File
- Deliverable
- BLAs for two plasma collection centers
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “no_evidence”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the second check.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Adma Biologics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-ADMA-022164 · Corrections policy